ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 64 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $3,212,105 | -65.8% | 337,052 | -60.6% | 0.00% | -66.7% |
| Q1 2023 | $9,402,074 | -21.9% | 854,734 | +5.1% | 0.00% | -25.0% |
| Q4 2022 | $12,042,000 | -3.7% | 813,622 | +24.3% | 0.00% | -20.0% |
| Q3 2022 | $12,510,000 | +7.9% | 654,678 | +20.3% | 0.01% | +25.0% |
| Q2 2022 | $11,596,000 | +40.0% | 544,188 | +26.5% | 0.00% | +100.0% |
| Q1 2022 | $8,285,000 | +84.6% | 430,262 | +98.8% | 0.00% | +100.0% |
| Q4 2021 | $4,489,000 | -48.1% | 216,403 | -40.2% | 0.00% | -66.7% |
| Q3 2021 | $8,655,000 | -10.6% | 362,035 | +2.0% | 0.00% | 0.0% |
| Q2 2021 | $9,686,000 | +5.6% | 354,880 | +11.9% | 0.00% | 0.0% |
| Q1 2021 | $9,176,000 | +183.4% | 317,203 | +175.5% | 0.00% | +200.0% |
| Q4 2020 | $3,238,000 | -61.1% | 115,117 | -59.5% | 0.00% | -66.7% |
| Q3 2020 | $8,334,000 | -0.9% | 284,446 | +2.3% | 0.00% | -25.0% |
| Q2 2020 | $8,407,000 | +10.9% | 278,019 | +9.3% | 0.00% | 0.0% |
| Q1 2020 | $7,584,000 | – | 254,439 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 10,542,790 | $314,175,000 | 35.62% |
| Bain Capital Life Sciences Investors, LLC | 3,979,292 | $118,583,000 | 20.06% |
| Omega Fund Management, LLC | 844,680 | $25,171,000 | 10.42% |
| Vivo Capital, LLC | 1,686,527 | $50,259,000 | 4.55% |
| Orbimed Advisors | 4,673,850 | $139,281,000 | 2.34% |
| RA Capital Management | 1,165,184 | $34,722,000 | 1.10% |
| Polar Capital LLP | 375,000 | $11,175,000 | 0.12% |
| CAAS CAPITAL MANAGEMENT LP | 22,413 | $668,000 | 0.07% |
| FMR LLC | 5,713,343 | $170,258,000 | 0.02% |
| Laurion Capital Management LP | 50,000 | $1,490,000 | 0.02% |